Latest Medical statistics Stories
BOTHELL, WA and VANCOUVER, April 25, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2012 financial results will be released on Thursday, May 3, 2012, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business. To access the webcast, log on to the Investor Relations page of the...
- 85% of clinical trials finish late because of trouble finding volunteers - 85% of patients wish they were better informed about clinical trials - 61% of patients don't know where to obtain information about trials - 77% of patients wish there were a secure and anonymous online tool to help them locate clinical trials in their area NEW YORK , April 24, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) launched Fox Trial Finder...
LADERA RANCH, Calif., April 16, 2012 /PRNewswire/ -- Advanced Biologics announced today that they will be presenting data at the American Academy of Neurosurgeons (AANS) meeting this week in Miami, FL showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP(®) when compared to rhBMP-2 (Infuse(®), Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis showed superiority for OsteoAMP(®) in producing fusions when compared...
QUÉBEC CITY, April 2, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Phase 3 "X-PECT" (Xeloda® + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda®) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial involving 468 patients in 65 sites in the U.S...
HAIFA, Israel and MILAN, March 14, 2012 /PRNewswire/ -- IBM (NYSE: IBM) today announced it has developed a unique biomedical analytics platform for personalized medicine that could enable doctors to better advise on the best course of medical treatment. This could lead to smarter and more personalized healthcare in a wide-range of areas, including cancer management, hypertension, and AIDS care. (Photo: http://photos.prnewswire.com/prnh/20120314/NY70125 )(Logo:...
UMass Medical School iHeal project uses emerging technologies to detect drug cravings and intervene Clinical researchers at the University of Massachusetts Medical School (UMMS) are combining an innovative constellation of technologies such as artificial intelligence, smartphone programming, biosensors and wireless connectivity to develop a device designed to detect physiological stressors associated with drug cravings and respond with user-tailored behavioral interventions that prevent...
HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011. Financial Results: Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same...
PHILADELPHIA, Feb. 16, 2012 /PRNewswire/ -- Premier Research Group Limited announces the opening of new state-of-the-art clinical research facilities located in Phoenix and Salt Lake City, increasing their testing facilities capacity by 50%. "We are excited to be expanding our existing clinical research facilities to accommodate more phase 1 and outpatient studies," stated Michael Kuss, Vice President, Analgesia. "These new facilities give us the capability to reach and house more...
SEATTLE, Feb. 7, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which Omeros believes expands opportunities for the product's clinical and regulatory success. OMS302 is a proprietary combination of an anti-inflammatory active pharmaceutical ingredient (API) and an API that causes mydriasis (pupil dilation), each...
CLEVELAND, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow. Juventas recently...
